Listing 3 - Actual negotiations

Indication:

Zepzelca, in combination with atezolizumab, for the first-line maintenance treatment of extensive-stage small cell lung cancer in adult patients whose disease has not progressed following induction therapy with atezolizumab, carboplatin and etoposide

Indication:

For the treatment of adults with folate receptor-alpha positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have received one to three prior systemic treatment regimens

Indication:

In combination with atezolizumab, for the first-line maintenance treatment of extensive-stage small cell lung cancer in adult patients whose disease has not progressed following induction therapy with atezolizumab, carboplatin and etoposide.

Indication:

​For the treatment of locally advanced or metastatic extra-pancreatic (ep-NET) or pancreatic neuroendocrine tumours (nPNET).

Indication:

Psychotic disorders, mood disorders, and major depressive disorder

Indication:

For the treatment of primary biliary cholangitis (PBC), in combination with ursodeoxycholic acid (UDCA) in adults who have an inadequate response to UDCA alone, or as monotherapy in adults unable to tolerate UDCA.

Indication:

Luveris, for the stimulation of follicular development in women, as part of an assisted procreation activity, administered concomitantly with follitropin

Indication:

For use by women of reproductive potential to prevent pregnancy

Indication:

For the stimulation of follicular development in women, as part of an assisted procreation activity, administered concomitantly with follitropin

Indication:

In combination with cisplatin and gemcitabine, for the first-line treatment of adults with metastatic or with recurrent, locally advanced nasopharyngeal carcinoma (NPC).